{"collection_id":"ccdi_mci","collection_name":"CCDI-MCI","cancer_types":"Various","tumor_locations":"Various","species":"Human","subjects":4407,"supporting_data":null,"description":"The Molecular Characterization Initiative (MCI) is a component of the National Cancer Institute’s\n(NCI) Childhood Cancer Data Initiative (CCDI). It offers state-of-the-art molecular testing at no\ncost to newly diagnosed children, adolescents, and young adults (AYAs) with central nervous system\n(CNS) tumors, soft tissue sarcomas (STS), certain rare childhood cancers (RAR), and certain\nneuroblastomas (NBL) treated at a Children’s Oncology Group (COG)–affiliated hospital. The goal of\nMCI is to enhance the understanding of genetic factors in pediatric cancers and to provide timely,\nclinically relevant findings to doctors and families to aid in treatment decisions and determine\neligibility for certain planned COG clinical trials.\nPlease see the\nDICOM converted whole slide hematoxylin and eosin stained images from the Molecular Characterization Initiative of the National Cancer Institute's Childhood Cancer Data Initiative (https://doi.org/10.5281/zenodo.11099086)\ninformation page to learn more about the images\nand any\nsupporting metadata for this collection, and to learn about attribution/citation requirements.","patients":4407,"studies":4447,"series":4576,"instances":21363,"size_TB":4.657,"modalities":["SM"],"licenses":[{"license_short_name":"CC BY 4.0","series":4576,"size_TB":4.657}]}